Impact of pre‐transplant donor specific antibodies detected by Luminex with negative microlymphocytotoxicity assay and flow crossmatch in live‐related renal transplant recipients
- 23 February 2023
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 37 (5) , e14935
Abstract
Introduction/Aim: The Luminex assay, where beads are coated with a single HLA antigen, has been shown to detect HLA antibodies with more sensitivity and specificity as compared to microlymphocytotoxicity (CDC) assay and flow cross match (FCXM). We report the impact of low Mean Flourescence intensity (MFI) pre‐transplant DSA by Luminex with negative CDC and FCXM on acute rejection, graft function, and survival.Methods: In this retrospective study between January 2015 to December 2021, 45 recipients had pre‐transplant anti‐HLA donor‐specific antibodies (DSAs) detected by Luminex. Two control groups of 45 patients each matched for age and gender, first with non‐DSA HLA antibodies and second with no antibodies by Luminex were selected to compare outcomes with DSA group.Results: In the DSA group of 45, 22 (48.8%) had class I (MFI mean 4043 ± 1909, range: 1096–7111), 20 (44.4%) class II (MFI mean 3601 ± 2310, range: 1031–9259), and 3 (6.6%) both class I (MFI mean 4746 ± 1922) and class II (MFI mean 3940 ± 2312) antibodies. Acute rejection episodes were reported in 15.6%, DSA group, 17.8% in non‐DSA, and 24.4% in no antibody group (p = .538). Death censored graft survival at 1 and 5 years was 98% and 93% in DSA group, 100% and 95% in non‐DSA and 93% and 85% in the no antibody group (p = .254).Conclusions: Patients with low MFI DSA pre‐transplant, with a negative CDC and FCXM under ATG induction, have similar graft outcomes at 1 and 5 years when compared to non‐DSA and no antibody groups.Keywords
This publication has 22 references indexed in Scilit:
- Pretransplant Immunologic Risk Assessment of Kidney Transplant Recipients With Donor-Specific Anti–Human Leukocyte Antigen AntibodiesTransplantation, 2014
- Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient deathTransplant Immunology, 2013
- Role and Value of Luminex®-Detected HLA Antibodies before and after Kidney TransplantationTransfusion Medicine and Hemotherapy, 2013
- Donor-Specific Antibodies Adversely Affect Kidney Allograft OutcomesJournal of the American Society of Nephrology, 2012
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney TransplantationJournal of the American Society of Nephrology, 2010
- Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevantHuman Immunology, 2009
- Clinical Relevance of Pretransplant Donor-Specific HLA Antibodies Detected by Single-Antigen Flow-BeadsTransplantation, 2009
- Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization TherapyTransplantation, 2008
- Pretransplant Donor-Specific Antibodies in Cytotoxic Negative Crossmatch Kidney Transplants: Are They Relevant?Transplantation, 2008
- Significance of the Positive Crossmatch Test in Kidney TransplantationNew England Journal of Medicine, 1969